Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1998 Oct;53(10):835–841. doi: 10.1136/thx.53.10.835

Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma

Y Nakamura 1, M Hoshino 1, J J Sim 1, K Ishii 1, K Hosaka 1, T Sakamoto 1
PMCID: PMC1745086  PMID: 10193369

Abstract

BACKGROUND—It has been reported that pranlukast reduces the antigen induced immediate and late phase asthmatic responses, airway hyperreactivity to acetylcholine, and pulmonary eosinophil accumulation in guinea pigs. A study was undertaken to test the hypothesis that pranlukast may reduce the number of inflammatory cells in the bronchial mucosa of patients with asthma.
METHODS—A double blind, placebo controlled study was performed in 17 mild to moderate asthmatic subjects to examine changes in inflammatory cell infiltration in response to pranlukast (225 mg orally twice per day for four weeks). Comparisons of the mean daily β2 agonist use, symptom score, FEV1 percentage predicted, and airway methacholine responsiveness were made before and after treatment. Using fibreoptic bronchoscopy, bronchial biopsy specimens were obtained before and after treatment with either pranlukast (n = 10) or placebo (n = 7). Immunohistology was performed using monoclonal antibodies for CD3, CD4, CD8, CD68, NP57, AA1, EG1, EG2, γGTP and CD19.
RESULTS—When the pranlukast and placebo treated groups were compared there were decreases in β2 agonist use, symptom score, and airway methacholine responsiveness after pranlukast but no increase in FEV1 was seen. The clinical response in patients treated with pranlukast was accompanied by a reduction in CD3 (median difference -37, 95% confidence interval (CI) -69 to -1; p<0.05), CD4 (median difference -28, 95% CI -49 to -8; p<0.01), AA1 (median difference -15, 95% CI -26 to 0; p<0.05) and EG2 positive cells (95% CI -35 to 0; p<0.05), but not in EG1 positive eosinophils, γGTP positive cells, and CD19 positive plasma cells.
CONCLUSIONS—These results support the view that pranlukast may act by inhibition of bronchial inflammation in patients with asthma.



Full Text

The Full Text of this article is available as a PDF (160.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azzawi M., Bradley B., Jeffery P. K., Frew A. J., Wardlaw A. J., Knowles G., Assoufi B., Collins J. V., Durham S., Kay A. B. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis. 1990 Dec;142(6 Pt 1):1407–1413. doi: 10.1164/ajrccm/142.6_Pt_1.1407. [DOI] [PubMed] [Google Scholar]
  2. Dahlén S. E., Hedqvist P., Hammarström S., Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature. 1980 Dec 4;288(5790):484–486. doi: 10.1038/288484a0. [DOI] [PubMed] [Google Scholar]
  3. Drazen J. M., Austen K. F., Lewis R. A., Clark D. A., Goto G., Marfat A., Corey E. J. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci U S A. 1980 Jul;77(7):4354–4358. doi: 10.1073/pnas.77.7.4354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Drazen J. M. Comparative contractile responses to sulfidopeptide leukotrienes in normal and asthmatic human subjects. Ann N Y Acad Sci. 1988;524:289–297. doi: 10.1111/j.1749-6632.1988.tb38552.x. [DOI] [PubMed] [Google Scholar]
  5. Ferreri N. R., Howland W. C., Stevenson D. D., Spiegelberg H. L. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am Rev Respir Dis. 1988 Apr;137(4):847–854. doi: 10.1164/ajrccm/137.4.847. [DOI] [PubMed] [Google Scholar]
  6. Foster A., Chan C. C. Peptide leukotriene involvement in pulmonary eosinophil migration upon antigen challenge in the actively sensitized guinea pig. Int Arch Allergy Appl Immunol. 1991;96(3):279–284. doi: 10.1159/000235508. [DOI] [PubMed] [Google Scholar]
  7. Fujimura M., Sakamoto S., Kamio Y., Matsuda T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med. 1993 Feb;87(2):133–138. doi: 10.1016/0954-6111(93)90141-l. [DOI] [PubMed] [Google Scholar]
  8. Hua X. Y., Dahlén S. E., Lundberg J. M., Hammarström S., Hedqvist P. Leukotrienes C4, D4 and E4 cause widespread and extensive plasma extravasation in the guinea pig. Naunyn Schmiedebergs Arch Pharmacol. 1985 Aug;330(2):136–141. doi: 10.1007/BF00499906. [DOI] [PubMed] [Google Scholar]
  9. Israel E., Rubin P., Kemp J. P., Grossman J., Pierson W., Siegel S. C., Tinkelman D., Murray J. J., Busse W., Segal A. T. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med. 1993 Dec 1;119(11):1059–1066. doi: 10.7326/0003-4819-119-11-199312010-00001. [DOI] [PubMed] [Google Scholar]
  10. Marom Z., Shelhamer J. H., Bach M. K., Morton D. R., Kaliner M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis. 1982 Sep;126(3):449–451. doi: 10.1164/arrd.1982.126.3.449. [DOI] [PubMed] [Google Scholar]
  11. Nakagawa N., Obata T., Kobayashi T., Okada Y., Nambu F., Terawaki T., Furuya T., Muryobayashi K., Sawada M., Aishita H. Effect of a peptide leukotriene receptor antagonist, ONO-1078, on guinea-pig models of asthma. Eur J Pharmacol. 1993 Apr 28;235(2-3):211–219. doi: 10.1016/0014-2999(93)90139-9. [DOI] [PubMed] [Google Scholar]
  12. Obata T., Okada Y., Motoishi M., Nakagawa N., Terawaki T., Aishita H. In vitro antagonism of ONO-1078, a newly developed anti-asthma agent, against peptide leukotrienes in isolated guinea pig tissues. Jpn J Pharmacol. 1992 Nov;60(3):227–237. doi: 10.1254/jjp.60.227. [DOI] [PubMed] [Google Scholar]
  13. Okubo T., Takahashi H., Sumitomo M., Shindoh K., Suzuki S. Plasma levels of leukotrienes C4 and D4 during wheezing attack in asthmatic patients. Int Arch Allergy Appl Immunol. 1987;84(2):149–155. doi: 10.1159/000234414. [DOI] [PubMed] [Google Scholar]
  14. Redkar-Brown D. G., Aharony D. Inhibition of antigen-induced contraction of guinea pig trachea by ICI 198,615. Eur J Pharmacol. 1989 Jun 8;165(1):113–121. doi: 10.1016/0014-2999(89)90776-0. [DOI] [PubMed] [Google Scholar]
  15. Reiss T. F., Altman L. C., Chervinsky P., Bewtra A., Stricker W. E., Noonan G. P., Kundu S., Zhang J. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol. 1996 Sep;98(3):528–534. doi: 10.1016/s0091-6749(96)70086-6. [DOI] [PubMed] [Google Scholar]
  16. Rinkema L. E., Bemis K. G., Fleisch J. H. Production and antagonism of cutaneous vascular permeability in the guinea pig in response to histamine, leukotrienes and A23187. J Pharmacol Exp Ther. 1984 Sep;230(3):550–557. [PubMed] [Google Scholar]
  17. Snyder D. W., Cho H. L., Gilmore J. Endogenously formed leukotriene C4 activates LTC4 receptors in guinea pig tracheal strips. Eur J Pharmacol. 1991 Mar 26;195(2):209–215. doi: 10.1016/0014-2999(91)90537-z. [DOI] [PubMed] [Google Scholar]
  18. Spector S. L., Smith L. J., Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med. 1994 Sep;150(3):618–623. doi: 10.1164/ajrccm.150.3.8087328. [DOI] [PubMed] [Google Scholar]
  19. Takishima T., Hida W., Sasaki H., Suzuki S., Sasaki T. Direct-writing recorder of the dose-response curves of the airway to methacholine. Clinical application. Chest. 1981 Nov;80(5):600–606. doi: 10.1378/chest.80.5.600. [DOI] [PubMed] [Google Scholar]
  20. Taniguchi Y., Tamura G., Honma M., Aizawa T., Maruyama N., Shirato K., Takishima T. The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J Allergy Clin Immunol. 1993 Oct;92(4):507–512. doi: 10.1016/0091-6749(93)90074-p. [DOI] [PubMed] [Google Scholar]
  21. Taylor G. W., Taylor I., Black P., Maltby N. H., Turner N., Fuller R. W., Dollery C. T. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989 Mar 18;1(8638):584–588. doi: 10.1016/s0140-6736(89)91611-5. [DOI] [PubMed] [Google Scholar]
  22. Taylor I. K., O'Shaughnessy K. M., Fuller R. W., Dollery C. T. Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991 Mar 23;337(8743):690–694. doi: 10.1016/0140-6736(91)90277-v. [DOI] [PubMed] [Google Scholar]
  23. Wardlaw A. J., Hay H., Cromwell O., Collins J. V., Kay A. B. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol. 1989 Jul;84(1):19–26. doi: 10.1016/0091-6749(89)90173-5. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES